XNW 27011
Alternative Names: ASP-546C; XNW 27; XNW-27011Latest Information Update: 26 Sep 2025
At a glance
- Originator Evopoint Biosciences
- Developer Astellas Pharma; Evopoint Biosciences
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Adenocarcinoma
- Phase I/II Solid tumours
Most Recent Events
- 26 Sep 2025 Efficacy and adverse event data from a phase I/II trial in Solid tumours presented at the presented at the 61st Annual Meeting of the American Society of Clinical Oncology 2025 (ASCO-2025)
- 30 Mar 2025 Phase-III clinical trials in Adenocarcinoma (Inoperable/Unresectable, Late-stage disease) in China (Parenteral)
- 30 Mar 2025 Astellas plans a global phase I/II trial